中国妇女低剂量口服避孕药使用者中脑卒中发病情况的前瞻性研究

目的 了解目前我国广泛应用的国产低剂量复方口服避孕药（COC）与脑卒中发病危险性的关系,以期降低COC的不良反应。方法 应用前瞻性队列研究的方法,于1997年7月至2000年6月在江苏太仓市和如东县25个乡镇随访比较44408名使用甾体激素避孕药（HC）和75230名使用IUD妇女的脑卒中发病率。结果 （1）HC队列出血型脑卒中的调整后发病率为34．74／10万,是IUD队列的2．72倍（P＜0．01）;HC队列45岁以下妇女出血型脑卒中的发病率明显高于IUD队列;停用HC10年以上者出血型脑卒中发病危险度为2．17（1．16,4．06）,仍显著高于IUD使用者。（2）国产低剂量COC当前使用者中出血型脑卒中发病危险性为非使用者3．60倍（1．73,7．53）,停用5年以内发病危险度达3．09（1．26,7．57）,但停用5年以后发病危险度明显下降。（3）在国产COC当前使用者中未发现梗塞型脑卒中发病率明显升高现象。（4）在国产低剂量COC使用者中,高血压可能是出血型脑卒中最重要的危险性因素。（4）在国产低剂量COC使用者中,高血压可能是出血型脑卒中最重要的危险性因素。结论 使用国产低剂量COC的妇女出血型脑卒中发病危险性明显升高,其对出血型脑卒中发病的影响可持续到停用以后,应进一步研究COC与高血压对出血型脑卒中发病的影响。     

Oral contraceptives and nonfatal myocardial infarction.

We obtained information on 107 women younger than 46 years who were discharged from a hospital with a diagnosis of acute myocardial infarction. In the series 26 women were otherwise apparently healthy and potentially childbearing. Among these 26 women, 20 (77%) were taking oral contraceptives just prior to admission, and one was taking conjugated estrogens. Among 59 control women, 14 (24%) were taking oral contraceptives and one was taking conjugated estrogens. The relative risk estimate, comparing oral contraceptive users with nonusers, is 14 with 90% confidence limits of 5.5 and 37. All but two of the 26 women were cigarette smokers. While this illness is rare in most healthy young women, the risk in women older than about 37 years who both smoke and take oral contraceptive appears to be high.     

Oral contraceptives, pregnancy, and endogenous oestrogen in gall stone disease--a case-control study

A case-control study of gall stone disease in women in relation to use of contraceptives, reproductive history, and concentrations of endogenous hormones was undertaken. The study population comprised 200 hospital patients with newly diagnosed gall stone disease, 182 individually matched controls selected from the community, and 234 controls who were patients in hospital. Use of oral contraceptives was associated with an increased risk of developing gall stones among young subjects but a decreased risk among older subjects. The risk of developing gall stone disease increased in association with increasing parity, particularly among younger women. The risk fell with increasing age at first pregnancy, independent of parity. Mean urinary excretion over 24 hours of oestrone, but not of pregnanediol, was significantly (p less than 0.05) greater for postmenopausal patients than controls. The age dependence of the relative risk associated with exposure to oral contraceptives and pregnancy suggests that there are subpopulations of women susceptible to early formation of gall stones after exposure to either oral contraceptives or pregnancy.     

Oral contraceptives and breast cancer: a national study

In a population based case-control study 433 New Zealand women aged 25-54 with newly diagnosed breast cancer were compared with 897 women selected at random from the electoral rolls. The relative risk of breast cancer in women who had ever used oral contraceptives was 0.94 (95% confidence interval 0.70 to 1.25). The relative risk in women aged 25-34 at diagnosis was estimated to be 2.2 (95% confidence interval 0.47 to 9.9) and in older women less than 1. Analyses of risk by duration of use of oral contraceptives, age at first use, and time since first use showed no adverse effect of the pill. In particular, there was no increased risk in women who had used oral contraceptives before the age of 25 or before their first pregnancy, even for prolonged periods. Given the high prevalence of use in New Zealand, this study provides strong evidence against the hypothesis that use of oral contraceptives at young ages increases the risk of breast cancer.     

Cancer of the liver and the use of oral contraceptives

A case-control study of the use of oral contraceptives was conducted among women certified as having died from cancer of the liver in the period 1979-82 and in the age range 20-44 years. An age matched group of women who died from other causes, not related to use of oral contraceptives, in the same period were used as controls. Information about use of oral contraceptives was obtained from the general practitioners' notes for both cases and controls. Information was obtained for 30 women with histologically confirmed liver cancer, 19 with hepatocellular carcinoma and 11 with cholangiocarcinoma, and for 147 controls. The results were analysed after adjusting for age at diagnosis and year of birth and showed that use of oral contraceptives was associated with a significantly (p less than 0.05) raised relative risk for hepatocellular carcinoma of 3.8 (95% confidence interval 1.0 to 14.6) and use for eight years or more was associated with a significantly (p less than 0.01) increased relative risk of 20.1 (2.3 to 175.7). There were no apparent increases in risk for cholangiocarcinoma. Despite the small number of cases in this study and the methodological problems in assessing use of oral contraceptives from general practitioners' notes, the results were consistent with other similar studies. Although in the United Kingdom primary liver cancer remains an exceptionally rare disease, especially in young women, further research on the role of oral contraceptives is needed in those countries where it is a much more common disease.     

The relationship of tubal infertility to barrier method and oral contraceptive use

We studied past contraceptive use in 283 nulliparous infertile women who had a diagnosis of tubal adhesions or occlusion and in 3833 women admitted for delivery at seven collaborating hospitals from 1981 to 1983. The relative risk of tubal infertility associated with barrier contraceptive use or oral contraceptive use was calculated using multivariate logistic regression to control for confounding by region, age, religion, education, smoking, number of sexual partners, time since menarche, and use of other contraceptive methods. Women who had ever used barrier methods of contraception were at a significantly decreased risk of tubal infertility (relative risk = 0.6; 95% confidence limits, 0.5 and 0.8). When type of barrier method used for the longest time was evaluated, those who used the diaphragm or condoms plus spermicides were at lower risk than those who used condoms or spermicides alone. Overall, past use of oral contraceptives neither increased nor decreased a woman's risk of tubal infertility, but there was evidence that the association between oral contraceptives and tubal infertility may vary by the amount of estrogen and type of progestogen in the oral contraceptive used. We conclude that contraceptive users who use barrier methods that combine both a mechanical and chemical barrier, such as diaphragms, cervical caps, and condoms plus spermicides, have the clearest protection against tubal damage.     

Serum copper in rural women taking combined oral contraceptive

This prospective case-control study included 78 women between 15 to 45 years of age from rural area to see changes in serum copper level as a consequence of oral contraceptive use. Among the subjects, 34 women were included as controls because of not taking any form of hormonal contraceptives neither during the time of selection nor during one-year period prior to the study. Women in the control group were motivated to consume oral pill (Sukhi) for 3 consecutive cycles. At the 3(rd) month, 25 such women became available and henceforth included as cases on longitudinal basis. Another 44 women were randomly selected as cases on the basis of using combined oral contraceptives (Sukhi) for a duration of 4 months onwards. Considering different duration of oral contraceptive (OC) use, subjects were grouped as follows: Group I (n=34)--> controls, Group II (n=25)--> 3 months, Group III (n=17)--> 4 months - 2 years and Group IV (n=27)--> >2 years. Finally, 103 samples of blood (34 from controls and 69 from oral contraceptives users) were collected for estimation of Serum Copper (mgm/dl) by Atomic Absorption Spectrometry using UNICAM-AA Spectrometer. Mean+/-SD of Serum Copper significantly increased in all 3 contraceptive groups in comparison to controls (p<0.001). Further study including larger population from rural area was recommended to see correlation among serum copper and other trace elements with side effects of hormonal contraceptives. This preliminary study tried to explore the possibility of establishing biochemical monitoring of serum trace elements in OC users.     

Oral contraceptives,serum folate,and hematologic status

Previous reports have suggested deleterious effects on folate balance in users of contraceptives. A study of folate in 526 women attending a family-planning clinic demonstrated, both with the Lactobacillus casei assay and with a new radioassay, that the mean serum folate level for women taking oral contraceptives was not significantly lower than that for women in a control group. There was no correlation between serum folate level and length of time oral contraceptives were taken. Also, there was no macrocytosis or hypersegmentation of polymorphonuclear leukocytes and no case of macrocytic anemia in the 280 users of oral contraceptive agents. Probably, oral contraceptive agents do not cause folate deficiency anemia in otherwise normal subjects.     

Breast cancer and oral contraceptives: findings in Oxford-Family Planning Association contraceptive study

Among the 17 032 women taking part in the Oxford-Family Planning Association contraceptive study, 72 were first diagnosed as having breast cancer between the date they were admitted to the study and 1 September 1980. The relative risk of developing the disease in women who had used oral contraceptives in comparison with those who had never used them was estimated to be 0.96 (95% confidence limits 0.59 to 1.63). Among women aged under 35 years, the corresponding relative risk (based on only 14 women with breast cancer) was estimated to be 0.61. No relation was apparent between the risk of developing breast cancer and duration of oral-contraceptive use or interval since first oral-contraceptive use in any age group. The data in this study are thus reassuring; but observations based on women with long-term use of oral contraceptives, especially those starting to use the preparations at an early age, are few.     

糖尿病合并尿路和肺部感染及其危险因素对比分析

目的探讨糖尿病合并尿路和肺部感染的临床特点、病原体及其危险因素。方法对比分析205例糖尿病合并尿路和肺部感染的危险因素。结果与感染有关的共同因素有5个,肺部与尿路感染均显示与年龄、病程、空腹血糖、血浆蛋白及并发症有关(P<0.05或0.01);其中与尿路感染有关的因素有5个,性别中以女性感染率明显增高为表现,与尿潴留因素(尿路结石、前列腺肥大、神经原性膀胱)及泌尿系侵入性操作明显有关(P<0.01)。结论糖尿病合并尿路感染部分隐性发病,与尿路感染发生明显有关的危险因素有:性别、合并尿潴留状态、泌尿系侵入性操作等。抗生素的使用不当可使真菌感染增多。使用胰岛素控制血糖、合理应用抗生素、积极治疗并发症、解除尿潴留因素及尽量避免泌尿系侵入性操作是防治糖尿病合并尿路感染的主要措施。     

Vitamin A,pregnancy, and oral contraceptives

It has been shown that women receiving oral contraceptives have increased levels of serum vitamin A. High vitamin A levels may constitute a teratogenic hazard. Women who conceive soon after discontinuing oral contraceptive therapy may be especially at risk to this hazard. An increase in vitamin A levels in women taking oral contraceptives has been confirmed. During early pregnancy there is no significant difference in vitamin A levels between women who have recently been taking oral contraceptives and those who have not. The authors were not able to demonstrate that either taking oral contraceptives shortly before pregnancy or a high vitamin A level during the first trimester of pregnancy, comparable to that of a woman taking oral contraceptives, has any detrimental effect on the outcome of pregnancy. It seems unlikely that women conceiving soon after discontinuing oral contraceptive, has any detrimental effect on the outcome of pregnancy. It seems unlikely that women conceiving soon after discontinuing oral contraceptive therapy run any teratogenic risk from increased vitamin A levels.     

Oral contraceptive steroid plasma concentrations in smokers and non-smokers

A study was performed to find out whether the overall rate of metabolism of oral contraceptives is affected by smoking and whether this explains the increased incidence of cardiovascular disease in users of oral contraceptives who smoke. Plasma ethinyloestradiol and norgestrel concentrations in 311 women using oral contraceptives were similar in smokers and non-smokers. The overall rate of metabolism of contraceptive steroids does not therefore seem to be affected by cigarette smoking.     

Serum zinc status of rural women taking combined OC

This prospective case-control study was undertaken on 78 women between 15 to 45 years of age from rural area to see alteration of serum zinc due to oral contraceptive (OC) use. Of the subjects, 34 women was taken as controls having no history of taking any form of hormonal contraceptives neither during the time of selection nor during one-year period prior to the study. All of the women in the control group were advised to start consuming oral pill (Sukhi) for 3 consecutive cycles and at the 3(rd) month, 25 women were taken as cases on longitudinal basis. Another 44 women were randomly selected as cases on the basis of using combined oral contraceptives (Sukhi) for 4 months onwards. Subjects were classified as follows on the basis of duration of oral contraceptive use: Group I (n=34) -- controls, Group II (n=25) -- 3 months, Group III (n=17) -- 4 months -- 2 years and Group IV (n=27) -- >2 years. Finally, 103 samples of blood (34 from controls and 69 from oral contraceptives users) were collected for estimation of Serum Zinc (microg/dl) by Atomic Absorption Spectrometry using UNICAM - AA Spectrometer. MeanSD of Serum Zinc significantly reduced in all 3 contraceptive groups in comparison to controls (p<0.001). It was recommended to carry out further study including larger population from rural area to elucidate alteration in serum zinc and other trace elements to correlate with side effects caused by hormonal contraceptive so that attempt could be made to mitigate those.     

Oral contraceptives use and liver tumours: a review

Of the nine epidemiologic controlled studies reporting on the relationship between oral contraceptives use and hepatic tumours, three have findings specifically on the association of oral contraceptives use and hepatocellular adenomas. The strength of this association is reported to be dependent more on long-term oral contraceptive use. Three other studies have reported similar relationships of oral contraceptives use with hepatocellular carcinoma, whereas the remaining three other studies have reported no association between oral contraceptives use and hepatocellular carcinoma. There is however, an increased risk of hepatocellular carcinoma as the duration of oral contraceptives use increases. The risk of developing hepatocellular adenomas is higher in oral contraceptives users over 30 years of age than in the younger age groups. These tumours occur more often in oral contraceptive users taking pills with high doses of estrogens and progestogens; while they are not only associated with oral contraceptives containing mestranol, but also those containing ethinylestradiol.     

Ureteric complications following renal transplantation: An eight years experience.

Objectives: Ureteric complications (UCs) following renal transplantation (RT) cause significant morbidity and ureteric stents are employed to bridge the vesico-ureteric anastomosis with a view to preventing these complications. The purpose of this study was to examine the incidence of UCs and outcomes following RT in both stented (STG) and non-stented groups (NSTG) of RT patients. Methods: This is a retrospective study of a cohort of 650 consecutive RTs [STG (N=267; 41%) and NSTG (N=383; 59%)] performed over a period of 8 years, where the data were retrieved from a prospectively maintained computerised database and case-notes. Results: The overall incidence of UCs was 6.5% (42/650), which consisted of ureteric obstruction (UO) in 4.3% (28) and ureteric leak (UL) in 2.2%(14) of patients. The incidence of UO was significantly high in the NSTG compared to the STG (6.3% vs.1.5%; P=0.002). However, the incidence of UL (3.4% vs.1.3%; P=0.1) and post-transplant urinary tract infection (UTI) (44% vs.41%; P=0.57) were not significantly different between the STG and NSTG groups. UO and UL were associated with significantly high incidence of UTI (P=0.001 and 0.01, respectively). All UCs were managed successfully without allograft loss. Conclusions: Routine stenting of ureteric anastomosis resulted in reduced incidence of UO without concomitant increased risk of UTI. Key words: Renal transplantation, vesico-ureteric anastomosis, stent, complications.     

Do oral contraceptives prevent rheumatoid arthritis?

Two studies have suggested that the risk of rheumatoid arthritis in women using oral contraceptives is less than half that of nonusers. When a third study from the Mayo Clinic failed to confirm these findings, it was criticized for inclusion of ineligible subjects, misclassification of oral contraceptive use, and inadequate statistical power. Recent expansion of the Mayo Clinic's data resources provided a unique opportunity to resolve the controversy, and a new population-based case-control study was undertaken. In comparison with the previous study, the new investigation had 2.2 times as many eligible cases and more complete ascertainment of oral contraceptive use via access to the records of Planned Parenthood of Minnesota. Comparing any prior use of oral contraceptives with never having used them, the relative risk of rheumatoid arthritis estimated from 182 cases and their 182 matched controls was 1.1 (95% confidence interval 0.7 to 1.7). The relative risk for current use was 1.3 (95% confidence interval, 0.7 to 2.4). The lack of a protective effect was independent of age, disease severity, and disease end point (date of confirmed diagnosis or symptom onset).     

274例女性尿路感染影响因素分析

目的探讨引起女性尿路感染的危险因素。方法对274例女性尿路感染的危险因素进行分析。结果女性尿路感染在年龄、性交史、糖尿病、是否绝经、是否有憋尿习惯等方面差异有统计学意义（P〈0．05）；较大的年龄是女性UTI的危险因素（OR〉1，P〈O．05），而没性交史、未患糖尿病、未绝经、没有憋尿习惯等是女性UTI的保护因素（OR〈1，P〈0．05）。结论女性尿路感染和多种因素关系密切，做好相关人群UTI宣教工作很有必要。     

急性脑卒中并发泌尿系感染分析

目的 探讨急性脑卒中患者并发泌尿系感染的高发因素及其对预后的影响，寻求降低泌尿系染率的方法。方法 分析我科56例急性脑卒中患者，泌尿系感染率与患者年龄、病种、病情、基础疾病及预后的关系。结果 高龄、病情重、导尿、原有糖尿病、心脏病、肿瘤、免疫系统疾病及中风史者泌尿系感染率明显升高，病死率明显升高。结论 控制院内泌尿系感染可有效提高脑卒中救治成功率。     

Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: findings in a large cohort study of women of childbearing age

Since the start in 1968 of the Oxford Family Planning Association contraceptive study 31 women have developed ulcerative colitis and 18 have developed Crohn's disease, giving incidences of 0.15 and 0.09/1000 woman years respectively. The incidence of ulcerative colitis in women who were non-smokers on entry to the study was 0.17/1000 woman years and the incidence in smokers was 0.11/1000 woman years. The findings for Crohn's disease were entirely different, the corresponding incidences being 0.05 and 0.17/1000 woman years respectively. Both ulcerative colitis and Crohn's disease were more common among women currently using oral contraceptives than among those not doing so. Incidences per 1000 woman years for ulcerative colitis were 0.26 in users and 0.11 in non-users; for Crohn's disease the incidences were 0.13 and 0.07 respectively. Though the association between the use of oral contraceptives and chronic inflammatory bowel disease cannot be regarded as established, the effects of smoking have been shown consistently in many studies. This observation provides an important clue to the aetiology of chronic inflammatory bowel disease.     

口服避孕药对多囊卵巢综合征患者性功能的影响

目的 评估口服避孕药（oral contraceptives,OCs）对多囊卵巢综合征（polycystic ovary syndrome,PCOS）患者性功能的影响,并分析其女性性功能障碍（female sexual dysfunction,FSD）发生的危险因素。方法 研究共纳入210例门诊PCOS患者,其中服用口服避孕药者126例（OC组）,未服用者84例（NOC组）。采用网络女性性功能指数（Female Sexual Function Index,FSFI）量表,并补充附加问题,评估参与者的基本信息、避孕方法、性伴侣关系稳定程度、孕产史等多个女性性功能的潜在影响因素。结果 OC组FSFI总分中位数为26.35分,50.79%表现为FSD高风险;NOC组FSFI总分中位数26.85分,47.62%显示FSD高风险;两组得分相比差异无统计学意义（P=0.635）。在口服避孕药使用者中,服用35 μg炔雌醇/2 mg醋酸环丙孕酮、30 μg炔雌醇/3 mg屈螺酮、30 μg炔雌醇/150 μg去氧孕烯三种不同成分口服避孕药的患者之间,FSFI得分差异无统计学意义。经Logistic回归分析,性生活是否主动、伴侣关系是否稳定是PCOS患者性功能的影响因素。结论 PCOS患者中,是否服用口服避孕药、服用不同类型口服避孕药的患者之间性功能评分差异均无统计学意义。PCOS患者性功能的潜在影响因素中,性生活是否主动、伴侣关系是否稳定与FSD高风险的发生相关。